These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35330486)

  • 1. Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists.
    Roldán V; Martínez-Montesinos L; López-Gálvez R; García-Tomás L; Lip GYH; Rivera-Caravaca JM; Marín F
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort.
    Rivera-Caravaca JM; Roldán V; Martínez-Montesinos L; Vicente V; Lip GYH; Marín F
    J Gen Intern Med; 2023 Feb; 38(2):315-323. PubMed ID: 35411538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry.
    Esteve-Pastor MA; Ruiz-Ortiz M; Muñiz J; Roldán-Rabadán I; Otero D; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F
    Front Cardiovasc Med; 2022; 9():856222. PubMed ID: 35586656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry.
    Rivera-Caravaca JM; Badimón L; Ferreira-Gonzalez I; Gómez-Doblas JJ; Roca-Luque I; Lekuona I; Jiménez-Candil J; Rodríguez-Padial L; González-Juanatey C; Calvo-Jambrina R; Fácila L; Ruiz-Ortiz M; Anguita M; Marín F
    Europace; 2022 Jan; 24(1):4-11. PubMed ID: 34115857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial Fibrillation Better Care Pathway Adherent Care Improves Outcomes in Chinese Patients With Atrial Fibrillation.
    Guo Y; Imberti JF; Kotalczyk A; Wang Y; Lip GYH;
    JACC Asia; 2022 Aug; 2(4):422-429. PubMed ID: 36339366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.
    Mearns ES; White CM; Kohn CG; Hawthorne J; Song JS; Meng J; Schein JR; Raut MK; Coleman CI
    Thromb J; 2014; 12():14. PubMed ID: 25024644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry.
    Proietti M; Lip GYH; Laroche C; Fauchier L; Marin F; Nabauer M; Potpara T; Dan GA; Kalarus Z; Tavazzi L; Maggioni AP; Boriani G;
    Europace; 2021 Feb; 23(2):174-183. PubMed ID: 33006613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Clin Ther; 2018 Jan; 40(1):114-122. PubMed ID: 29275065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.
    Pignatelli P; Pastori D; Vicario T; Bucci T; Del Ben M; Russo R; Tanzilli A; Nardoni ML; Bartimoccia S; Nocella C; Ferro D; Saliola M; Cangemi R; Lip GY; Violi F
    Europace; 2015 Aug; 17(8):1223-8. PubMed ID: 25995397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation.
    Zulkifly H; Cheli P; Lutchman I; Bai Y; Lip GYH; Lane DA
    Thromb Res; 2020 Aug; 192():12-20. PubMed ID: 32416364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
    Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
    Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry.
    Romiti GF; Proietti M; Vitolo M; Bonini N; Fawzy AM; Ding WY; Fauchier L; Marin F; Nabauer M; Dan GA; Potpara TS; Boriani G; Lip GYH;
    BMC Med; 2022 Sep; 20(1):326. PubMed ID: 36056426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists.
    Zulkifly HH; Pastori D; Lane DA; Lip GYH
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.